Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
Table 4
Clinical characteristics of vaccination group and control group.
Vaccination group
Control group
P value
30
18
Age
63.5 ± 10.2
66.4 ± 10.3
0.3355
Sex (male/female)
19/11
15/3
0.1956
Visceral metastases
15 (50.0%)
12 (66.7%)
0.3693
Number of visceral metastatic sites
0.63 ± 0.76
1.00 ± 0.84
0.1417
Prior chemotherapy
27 (90.0%)
17 (94.4%)
0.9999
ECOG PS
0
13 (43.3%)
8 (44.4%)
0.4002
1
14 (46.7%)
6 (33.3%)
2
3 (10.0%)
4 (22.3%)
ECOG PS: Eastern Cooperative Oncology Group performance status.
